Astellas Pharma (United States)

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. Pfizer (United States)美国5
2. Astellas Pharma (Netherlands)荷兰3
3. Vanderbilt University Medical Center美国3
4. Analysis Group (United States)美国2
5. Humana (United States)美国2
6. University of Southern Denmark丹麦2
7. RTI Health Solutions美国2
8. Karolinska Institutet瑞典2

按月发文

逐年被引

最新文献

1. 1
   Managing Drug Interactions with Enzalutamide in Patients with Prostate Cancer: A PodcastDrug Safety20250
2. 2
   Might We Come Together on a Paradigm Shift to Manage ICSRs with a Decentralized Data Model?Drug Safety20251
3. 3
   Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study programPharmacoepidemiology and Drug Safety20240
4. 4
   Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug EfficacyDrug Safety202421
5. 5
   Treatment Patterns and FLT3 Mutation Testing Among Patients with Acute Myeloid Leukemia in China: A Retrospective Observational StudyTherapeutics and Clinical Risk Management20241
6. 6
   Inventory of real‐world data sources in Japan: Annual survey conducted by the Japanese Society for Pharmacoepidemiology Task ForcePharmacoepidemiology and Drug Safety202329
7. 7
   Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort StudyDrug Safety202125
8. 8
   Suitability of databases in the Asia‐Pacific for collaborative monitoring of vaccine safetyPharmacoepidemiology and Drug Safety20219
9. 9
   Validating Intelligent Automation Systems in Pharmacovigilance: Insights from Good Manufacturing PracticesDrug Safety202143
10. 10
    Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United KingdomPharmacoepidemiology and Drug Safety202030

高被引文献

1. 1
   Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14Drug Safety201554
2. 2
   Validating Intelligent Automation Systems in Pharmacovigilance: Insights from Good Manufacturing PracticesDrug Safety202143
3. 3
   Challenges facing drug utilization research in the Latin American regionPharmacoepidemiology and Drug Safety202031
4. 4
   Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United KingdomPharmacoepidemiology and Drug Safety202030
5. 5
   Inventory of real‐world data sources in Japan: Annual survey conducted by the Japanese Society for Pharmacoepidemiology Task ForcePharmacoepidemiology and Drug Safety202329
6. 6
   Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort StudyDrug Safety202125
7. 7
   Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug EfficacyDrug Safety202421
8. 8
   Burden of hospitalizations over time with invasive aspergillosis in the United States, 2004–2013BMC Public Health201920
9. 9
   Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims AnalysisDrug Safety201914
10. 10
    Suitability of databases in the Asia‐Pacific for collaborative monitoring of vaccine safetyPharmacoepidemiology and Drug Safety20219

主要发表期刊